Profile
Harish Shantharam is currently the Chief Financial Officer at UCLA Anderson School of Management.
Previously, he served as the Chief Financial & Accounting Officer at CymaBay Therapeutics, Inc. from 2023 to 2024.
Prior to that, he was the Vice President-Global Commercial Finance at Gilead Sciences, Inc. from 2011 to 2022.
He also held the position of Head-Business Development at Amgen, Inc. from 2004 to 2011.
Mr. Shantharam holds a graduate degree from The University of Texas at Arlington and an MBA from UCLA Anderson School of Management.
Former positions of Harish Shantharam
| Companies | Position | End |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Director of Finance/CFO | 2024-03-21 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2022-04-30 |
| AMGEN INC. | Corporate Officer/Principal | 2011-10-31 |
Training of Harish Shantharam
| UCLA Anderson School of Management | Masters Business Admin |
| The University of Texas at Arlington | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 1 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
- Stock Market
- Insiders
- Harish Shantharam
